Veterinary monoclonal antibody market seen hitting $1.85 billion by 2030

By AI, Created 11:42 AM UTC, May 20, 2026, /AGP/ – The veterinary monoclonal antibody market is projected to grow from $0.92 billion in 2025 to $1.85 billion by 2030, according to a new industry analysis. The report points to rising animal disease burdens, more veterinary hospitals and expanding use of targeted therapies as the main growth drivers.

Why it matters: - Veterinary monoclonal antibodies are moving from a niche tool to a broader treatment category in animal health. - The market’s projected growth signals more demand for targeted therapies in dogs, cats, horses and livestock. - Rising disease pressure in animals is pushing veterinarians toward more precise treatment options.

What happened: - The Business Research Company released an industry analysis on the veterinary monoclonal antibody market on May 5, 2026. - The report estimates the market will rise from $0.92 billion in 2025 to $1.06 billion in 2026. - The report forecasts the market will reach $1.85 billion by 2030. - The forecast implies a 14.8% compound annual growth rate through 2030. - The company also described monoclonal antibodies as specialized proteins used to identify and neutralize specific pathogens or toxins in animals.

The details: - The market’s near-term growth is tied to more cancers in dogs, more autoimmune disorders in pets, limited targeted treatment options, more veterinary hospitals and higher awareness of advanced veterinary therapies. - Longer-term growth is expected to come from advances in monoclonal antibody engineering and wider use of species-specific therapies. - The report also points to more funding for veterinary oncology and dermatology as a growth driver. - Personalized veterinary medicine is another factor expected to support demand. - The expansion of veterinary healthcare infrastructure worldwide is expected to help the market scale. - The report highlights growing use in canine cancer treatment, autoimmune diseases in dogs and veterinary dermatology. - Targeted pain management therapies are emerging as another application area. - Species-specific antibodies for cats, horses and livestock are also under development. - North America held the largest market share in 2025. - The report also covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - A free sample of the report is available here. - The full report is available here.

Between the lines: - The market forecast reflects a broader shift in veterinary care toward high-precision biologics, not just conventional treatments. - Disease spread in animals is becoming harder to ignore as climate change expands habitats for carriers such as ticks and mosquitoes. - A June 2024 GOV.UK report said animals slaughtered due to tuberculosis rose 5% in England to 21,298 and 17% in Wales to 11,197 between April 2023 and March 2024. - That trend underscores why targeted animal health treatments may draw more investment and adoption.

What’s next: - Market growth is likely to be shaped by how quickly veterinary clinics adopt monoclonal antibody products. - Continued research in oncology, dermatology and species-specific therapies could broaden approved uses. - Infrastructure investment in veterinary care and manufacturing capacity will likely influence how fast the market reaches the 2030 forecast.

The bottom line: - Veterinary monoclonal antibodies are forecast to post strong double-digit growth as animal disease burdens rise and precision medicine gains ground.